Ipamorelin vs CJC-1295 (No DAC)
Comprehensive side-by-side comparison of mechanisms, dosing, side effects, and research
Also: IPAM, NNC 26-0161
Ipamorelin is a synthetic pentapeptide growth hormone secretagogue developed by Novo Nordisk and derived from GHRP-1. It is researched mainly for stimulating the body's own growth hormone (GH) release, and was studied in humans primarily for postoperative ileus and gut motility rather than anti-aging. It is not an approved drug anywhere: it reached Phase II trials, was discontinued for insufficient efficacy, and is now sold only as a research chemical.
Also: CJC-1295 DAC, CJC-1295 no DAC
CJC-1295 is a synthetic analog of growth hormone-releasing hormone (GHRH), specifically a modified GHRH(1-29), engineered for a long duration of action. The form most people mean by CJC-1295 includes a Drug Affinity Complex (DAC) that binds blood albumin to extend its half-life to roughly 6 to 8 days, raising GH and IGF-I for days from a single injection. It was developed by ConjuChem, reached Phase II trials and was abandoned; it is not an approved drug and is sold only as a research chemical. A version without DAC (Modified GRF 1-29) acts for only about 30 minutes.
Key Comparison Insights
- Both peptides belong to the Growth Hormone category, suggesting similar primary applications.
- These GH secretagogues are frequently combined to enhance growth hormone release.
Detailed Comparison
| Attribute | Ipamorelin | CJC-1295 (No DAC) |
|---|---|---|
| Category | Growth Hormone | Growth Hormone |
| FDA Status | Not FDA Approved | Not FDA Approved |
| Clinical Status | Pre I II III IV FDA | Pre I II III IV FDA |
| Mechanism of Action | Ipamorelin is an agonist of the ghrelin / growth hormone secretagogue receptor (GHS-R1a) on the somatotroph cells of the anterior pituitary. Binding this receptor triggers intracellular signaling (Gq/phospholipase C, IP3 and calcium release) that makes the pituitary release stored GH in pulses, mimicking natural ghrelin. Its defining feature, established in the original 1998 characterization, is selectivity: at GH-releasing doses it does not meaningfully raise ACTH, cortisol, prolactin, FSH, LH or TSH, making it cleaner than older peptides like GHRP-2 and GHRP-6. Because it works on the pituitary's own GH reserves, the effect depends on a functioning pituitary and natural feedback loops stay in place. | CJC-1295 acts at the GHRH receptor on pituitary somatotroph cells, the same receptor the body's own GHRH uses, prompting the pituitary to synthesize and release growth hormone. Native GHRH is broken down within minutes; CJC-1295 with DAC carries a reactive group that covalently bonds to circulating albumin after injection, shielding it from breakdown and stretching its half-life from minutes to days. The sustained GH elevation drives the liver to produce IGF-I, the downstream hormone behind many of GH's tissue effects. There are two versions: with DAC (long-acting, albumin-binding) and without DAC (Modified GRF 1-29), which lacks the albumin tether. Because it works through the pituitary, it relies on the gland's own GH-producing capacity. |
| Common Dosing | 200-300 mcg 2-3x daily 2-3x daily | 100 mcg daily (no DAC) or 2 mg weekly (with DAC) Daily (no DAC) or 1-2x weekly (with DAC) |
| Administration | Subcutaneous injection | Subcutaneous injection |
| Typical Duration | 8-12 weeks typical | 8-12 weeks |
| Best Time to Take | Before bed or morning (fasted) | Before bed |
Possible Side Effects May vary by individual |
|
|
| Research Summary | The foundational work is Raun et al. (1998) in the European Journal of Endocrinology, which characterized ipamorelin in rats, pigs and isolated pituitary cells and named it the first selective growth hormone secretagogue, releasing GH without raising ACTH or cortisol even at doses far above the GH-releasing dose. Most rigorous data is preclinical. In humans, the compound was advanced into Phase II trials for postoperative ileus but was discontinued for insufficient efficacy. There are no large peer-reviewed human randomized controlled trials supporting the popular anti-aging, fat-loss, muscle-gain or recovery claims; those uses are extrapolations from the mechanism, not proven outcomes. Honestly stated: the receptor mechanism and GH-release effect are well documented, but human efficacy and long-term safety for wellness use are not established. | The key human study is Teichman et al. (2006) in the Journal of Clinical Endocrinology and Metabolism, a randomized, double-blind, placebo-controlled ascending-dose trial in healthy adults. A single subcutaneous injection raised mean plasma GH 2- to 10-fold for 6 days or more and IGF-I 1.5- to 3-fold for 9 to 11 days, with cumulative effects on repeat dosing, and was reported as safe and relatively well tolerated short-term. An earlier study showed once-daily CJC-1295 normalized growth in GHRH-knockout mice. Beyond pharmacokinetics and hormone levels, there are no large long-term human trials demonstrating clinical benefits like fat loss or muscle gain, so those claims are not established by published trials. Development was halted after Phase II; a single trial death was attributed by the attending physician to pre-existing coronary artery disease rather than the drug, which is reported but not independently confirmed. Bottom line: the GH and IGF-I-raising effect and long half-life are well supported, while real-world efficacy and long-term safety are not. |
Frequently Asked Questions: Ipamorelin vs CJC-1295 (No DAC)
What is the difference between Ipamorelin and CJC-1295 (No DAC)?
Ipamorelin is a growth hormone peptide that ipamorelin is a synthetic pentapeptide growth hormone secretagogue developed by novo nordisk and derived from ghrp-1. it is researched mainly for stimulating the body's own growth hormone (gh) release, and was studied in humans primarily for postoperative ileus and gut motility rather than anti-aging. it is not an approved drug anywhere: it reached phase ii trials, was discontinued for insufficient efficacy, and is now sold only as a research chemical. CJC-1295 (No DAC) is a growth hormone peptide that cjc-1295 is a synthetic analog of growth hormone-releasing hormone (ghrh), specifically a modified ghrh(1-29), engineered for a long duration of action. the form most people mean by cjc-1295 includes a drug affinity complex (dac) that binds blood albumin to extend its half-life to roughly 6 to 8 days, raising gh and igf-i for days from a single injection. it was developed by conjuchem, reached phase ii trials and was abandoned; it is not an approved drug and is sold only as a research chemical. a version without dac (modified grf 1-29) acts for only about 30 minutes. The main differences lie in their mechanisms of action and clinical applications.
Which is better, Ipamorelin or CJC-1295 (No DAC)?
Neither is universally "better" - the choice depends on your specific goals. Ipamorelin is typically used for growth hormone purposes, while CJC-1295 (No DAC) is used for growth hormone. Always consult with a healthcare provider to determine which may be appropriate for your situation.
Can Ipamorelin and CJC-1295 (No DAC) be used together?
Some peptide protocols combine multiple compounds for synergistic effects. However, using Ipamorelin and CJC-1295 (No DAC) together should only be considered under medical supervision, as both compounds have their own side effect profiles and potential interactions. Research on their combined use may be limited.